Bio Elpida, facilities dedicated to the development of bio-pharmaceuticals
120 m² of R&D Laboratories
Bio Elpida provides two types of R&D laboratories:
- 60 m² dedicated to the research and development for prokaryote cell programmes
- 60 m² dedicated to the research and development for eukaryotic cell programmes
Quality insurance and cGMP rules are applied as early as R&D phases
A distinctive feature of Bio Elpida is to apply quality insurance and cGMP as early as R&D phases. This approach ensures optimal transfer of processes to cGMP manufacturing and pharmaceutical zones as well as scale-up.